Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 974
countries
28
conditions
2 106

7 trials match your criteria

Diffuse large B-cell lymphoma refractory+1

Recruiting

Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab

Central nervous system lymphoma

Recruiting

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Lymphocyte adoptive therapy

Recruiting

Study on Extracellular Vesicles in Hematology Patients Treated with Brexucabtagene Autoleucel and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol

Diffuse large B-cell lymphoma

Recruiting

Study on Golcadomide for Patients with Relapsed or Refractory Aggressive Large B-Cell Lymphoma at High Risk of Relapse After CAR T-Cell Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide

Malignant lymphoid neoplasm

Recruiting

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540

Diffuse large B-cell lymphoma+7

Not yet recruiting

Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

B-cell lymphoma+2

Not recruiting

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lisocabtagene Maraleucel

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.